Paid Clinical Trials Fresno
Discover 204 paid clinical trials in Fresno, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in AdultsTesting the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Sponsor:
National Cancer Institute (NCI)
Location:
Code:
NCT04530565
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Blinatumomab
Bone Marrow Aspiration and Biopsy
Cyclophosphamide
Cytarabine
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaThoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Sponsor:
Children's Oncology Group
Location:
Code:
NCT05235165
Conditions
Metastatic Malignant Neoplasm in the Lung
Metastatic Osteosarcoma
Osteosarcoma
Eligibility Criteria
Sex: All
Age: 0 - 50
Healthy Volunteers: Not accepted
Interventions
Biospecimen Collection
Computed Tomography
Questionnaire Administration
Thoracoscopy
Thoracotomy
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral RegurgitationClinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
Sponsor:
Abbott Medical Devices
Location:
Code:
NCT03433274
Conditions
Mitral Regurgitation
Mitral Insufficiency
Mitral Valve Insufficiency
Cardiovascular Diseases
Valve Disease, Heart
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Tendyne Mitral Valve System
MitraClip System
Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot UlcersSafety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers
Sponsor:
KeraCure
Location:
Code:
NCT00330265
Conditions
Foot Ulcer
Diabetes
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
KC-002
Conventional Wound Therapy
Bupropion to Reduce Cancer Related Fatigue in Cancer SurvivorsBupropion to Reduce Cancer Related Fatigue in Cancer Survivors
Sponsor:
University of Rochester NCORP Research Base
Location:
Code:
NCT03996265
Conditions
Be Diagnosed With Cancer and Have Completed Systemic Therapy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bupropion Hydrochloride Controlled-release
Placebo Administration
Quality-of-Life Assessment
Questionnaire Administration
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerTrial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Sponsor:
Ferring Pharmaceuticals
Location:
Code:
NCT06510374
Conditions
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Nadofaragene Firadenovec
MFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric AdenocarcinomaMFOLFIRINOX Versus MFOLFOX with or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Sponsor:
Alliance for Clinical Trials in Oncology
Location:
Code:
NCT05677490
Conditions
Advanced Esophageal Adenocarcinoma
Advanced Gastric Adenocarcinoma
Advanced Gastroesophageal Junction Adenocarcinoma
Clinical Stage III Esophageal Adenocarcinoma AJCC V8
Clinical Stage III Gastric Cancer AJCC V8
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Fluorouracil
Leucovorin Calcium
Oxaliplatin
Irinotecan
Nivolumab
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
Sponsor:
Locus Biosciences
Location:
Code:
NCT05488340
Conditions
Urinary Tract Infections
Eligibility Criteria
Sex: Female
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
LBP-EC01 0.1 x IV dose
LBP-EC01 0.01x IV Dose
LBP-EC01 IV Infusion Dose
Placebo
LBP-EC01